Promega adding molecular-biology capacity with new plant

Promega is building a new cGMP facility that will turn out FDA-regulated molecular biology products. The 260,000 square-foot plant will bring 100 people onto the company's payroll, Contract Pharma reports.

Based in Madison, WI, the company plans to use most of the new space for manufacturing, including fixed production lines and flexible manufacturing areas. The plant will help Promega grow, particularly in products for diagnostics makers, such as sample prep systems and reagents used in medical tests, the company said.

"Molecular biology opens doors not only to new understanding of life, but to practical applications that enhance the health of our citizens," CEO Bill Linton said in a statement. "This building is our next step in expanding our product supply capabilities worldwide."

Promega is using environmentally friendly construction practices in building the new facility. Geothermal heating and cooling, bio-retention stormwater ponds, and dark-sky compliant lighting are among them.

- read the release from Promega
- get more from Contract Pharma

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.